A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer

Polly Niravath, Yee Lu Tham, Tao Wang, Angel Rodriguez, Claudette Foreman, Susan G. Hilsenbeck, Richard Elledge, Mothaffar Rimawi

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Background. Brain metastasis from breast cancer presents a significant threat to women’s health and quality of life. Capecitabine and sunitinib have shown some activity in this setting; there- fore, we conducted a single-arm phase II trial with these agents. Methods. Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m2 per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m2 per day for 2 weeks followed by a 1-week break) and sunitinib (37.5 mg daily, continuously). The primary end- point was progression-free survival (PFS).Results. Of 25 planned patientsthat would be required to detect a 4-month improvement (from 5 to 9 months) in median PFS with 80% power, 12 were enrolled, and the study was then closed forslow accrual. Median PFS was 4.7 months, and median overall survival was 10 months. In the CNS, 25% had progressive disease, and 83% experienced extra-CNS progression. The most common side effects were fatigue and nausea.Conclusion. In 12 evaluable patients studied, concurrent capecitabine and whole-brain radiation followed by capecita- bine and sunitinib did not extend PFS over historical rates and was associated with significant toxicity. Our study was small and closed due to slow accrual.

Original languageEnglish (US)
Pages (from-to)13
Number of pages1
JournalOncologist
Volume20
Issue number1
DOIs
StatePublished - 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer'. Together they form a unique fingerprint.

Cite this